Avenue Therapeutics, Inc. Releases 2025 Annual Report: Key Highlights and Risks for Investors

Avenue Therapeutics, Inc., a pharmaceutical preparations company based in Bay Harbor Islands, Florida, has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The report contains a comprehensive overview of business operations, financial position, and risks that are critical for investors and shareholders. Below is a detailed analysis of the most important disclosures and developments that may impact Avenue Therapeutics’ share price and investment outlook.

Key Points from the Annual Report

• Product Portfolio Changes: Avenue Therapeutics has terminated its license agreement for AJ201 with AnnJi Pharmaceutical Co., Ltd. and disposed of its equity interest in Baergic Bio, Inc., including rights to BAER‑101. This move results in the loss of two of its primary product candidates and narrows its focus to IV tramadol and ATX-04. This reduction in pipeline diversity represents a significant shift in business strategy and may impact future growth prospects.
• Going Concern Doubts: The company explicitly states there is substantial doubt about its ability to continue as a going concern. This is primarily due to ongoing losses since inception and expectations of continued losses for the foreseeable future. The company warns that this doubt may hinder its ability to obtain future financing and could result in delays or elimination of product development programs.
• Financial Position: Avenue Therapeutics has not generated any revenues from product sales and does not expect to do so in the near future. It will require substantial additional funding to continue operations and develop its remaining product candidates. Failure to raise this capital could force the company to delay, reduce, or eliminate programs and commercialization efforts.
• Stockholder Equity and Public Float: As of March 25, 2026, Avenue Therapeutics reported 3,294,635 shares of common stock outstanding. The aggregate market value of voting stock held by non-affiliates at the end of the most recent second fiscal quarter was \$571,897. The company is classified as a non-accelerated filer and a smaller reporting company.
• Stock Market Status: Avenue’s common stock is traded on the OTC Markets Group, Inc. (OTC Pink Open Market) under the symbol ATXI. The stock has been delisted from the Nasdaq Capital Market. The OTC Pink Open Market is a thinly traded market, lacking liquidity and subject to high volatility. There is a risk that Avenue’s stock may be considered a “penny stock,” making it difficult for brokers, dealers, and investors to sell shares.
• Fortress Biotech, Inc. Influence: Fortress Biotech, Inc. controls a majority of Avenue’s voting power and holds rights to receive significant share grants annually. This concentration of control may dilute other stockholders and could reduce the value of common stock. Avenue acknowledges that it may have received better terms from unaffiliated third parties in certain agreements with Fortress.
• Reliance on Third Parties: Avenue’s operations depend heavily on third parties for clinical data, regulatory compliance, manufacturing, and commercialization efforts. Inaccuracy or unreliability of third-party data may negatively impact regulatory approvals or business outcomes.
• Regulatory and Commercial Risks: The company faces significant regulatory hurdles, including the possibility of not receiving approval for its remaining product candidates, or delays due to scientific or regulatory reasons. Even with approval, products will remain subject to regulatory scrutiny. Public concern regarding opioid drug products such as IV tramadol could delay or limit regulatory approval, negatively impact market performance, and require inclusion of serious risk information in labeling.
• Competition and Intellectual Property: The pharmaceutical industry is highly competitive, with rapidly advancing technologies and strong emphasis on proprietary products. Avenue plans to continue expanding and protecting its intellectual property portfolio, but failure to maintain sufficient patent protection could allow competitors to develop similar products.

Summary of Risks That May Impact Share Price

• The loss of AJ201 and BAER‑101 reduces product diversity and growth potential.
• Substantial doubt about Avenue’s ability to continue as a going concern may deter new investment and depress share price.
• Failure to secure additional funding could result in the cessation of operations or elimination of development programs.
• Delisting from Nasdaq and trading on the OTC Pink increases liquidity risks and volatility, potentially making shares unattractive to institutional investors.
• Fortress Biotech’s control and dilution risk could negatively impact minority shareholders.
• Potential regulatory delays or public concern about opioid products may further limit commercial prospects.

Other Notable Disclosures for Shareholders

• Share Structure: The company has authorized 200,000,000 shares of common stock and 2,000,000 shares of preferred stock, with 250,000 preferred shares issued and outstanding.
• Legal Proceedings: Legal proceedings and unresolved staff comments are disclosed, but details are reserved for later sections of the report.
• Summary Risk Factors: The report includes a lengthy summary of risk factors covering business operations, finances, regulatory environment, commercialization, intellectual property, reliance on third parties, and influence of Fortress Biotech.

Conclusion

Avenue Therapeutics, Inc. faces serious challenges including a narrowed product pipeline, ongoing losses, liquidity and volatility risks following its Nasdaq delisting, and substantial doubt about its ability to continue as a going concern. The dominating influence of Fortress Biotech presents dilution risks for minority shareholders. The company’s fate hinges on its ability to secure additional funding and achieve regulatory approval for IV tramadol and ATX-04, its remaining product candidates. These developments and risk disclosures are highly material and may significantly impact Avenue’s share price, making them essential reading for investors and shareholders.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell Avenue Therapeutics, Inc. securities. Investors should perform their own due diligence and consult with a qualified financial advisor before making any investment decisions. All forward-looking statements are subject to risks and uncertainties as described in the company’s annual report.

View AVENUE THERAPEUTICS, INC. Historical chart here